Get the Stockscreener App
4.49
1.75%
-0.08
After Hours:
4.51
0.02
+0.45%
Orchestra Biomed Holdings Inc stock is traded at $4.49, with a volume of 111.61K.
It is down -1.75% in the last 24 hours and up +3.70% over the past month.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
See More
Previous Close:
$4.57
Open:
$4.52
24h Volume:
111.61K
Relative Volume:
0.50
Market Cap:
$262.76M
Revenue:
$33.48M
Net Income/Loss:
$-52.70M
P/E Ratio:
-3.4836
EPS:
-1.2889
Net Cash Flow:
$-49.45M
1W Performance:
-3.23%
1M Performance:
+3.70%
6M Performance:
+85.54%
1Y Performance:
+2.51%
1-Day Range:
$4.46
$4.635
1-Week Range:
$4.46
$4.83
52-Week Range:
$2.20
$5.424
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Name
Orchestra Biomed Holdings Inc
Sector
Industry
Phone
646-343-9298
Address
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
4.49 | 267.44M | 33.48M | -52.70M | -49.45M | -1.2889 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Initiated | TD Cowen | Buy |
| Aug-20-25 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-20-25 | Initiated | BTIG Research | Buy |
| Jan-02-25 | Initiated | Barclays | Overweight |
| Aug-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | B. Riley Securities | Buy |
| Jan-19-24 | Initiated | Jefferies | Buy |
| Feb-24-23 | Initiated | Piper Sandler | Overweight |
| Feb-07-23 | Initiated | Chardan Capital Markets | Buy |
View All
Orchestra Biomed Holdings Inc Stock (OBIO) Latest News
Jefferies cuts Orchestra BioMed stock price target on financing costs By Investing.com - Investing.com Australia
If You Invested $1,000 in Orchestra BioMed Holdings Inc (OBIO) - Stock Titan
Orchestra BioMed (OBIO) to Release Earnings on Wednesday - MarketBeat
Orchestra BioMed reports 2025 results, advances pivotal clinical trials - MSN
Trend Report: How do insiders feel about Orchestra BioMed Holdings IncRate Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates - MSN
Analysts’ Top Healthcare Picks: Orchestra BioMed Holdings (OBIO), Cardinal Health (CAH) - The Globe and Mail
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Highlights: Will Orchestra BioMed Holdings Inc benefit from geopolitical trends2026 Trends & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
HC Wainwright Has Optimistic Outlook of OBIO Q1 Earnings - MarketBeat
Orchestra BioMed Reports 2025 Results, Advances Pivotal Clinical Trials - MyChesCo
Top Executive Makes Bold Insider Move at Orchestra BioMed - TipRanks
Orchestra BioMed (NASDAQ:OBIO) Insider Purchases 10,000 Shares - MarketBeat
Orchestra BioMed (OBIO) director David Hochman buys 10,000 shares - Stock Titan
Orchestra BioMed (NASDAQ:OBIO) Raised to Hold at Wall Street Zen - MarketBeat
Orchestra BioMed (OBIO) First Profitable Quarter Tests Bearish Unprofitability Narrative - simplywall.st
Orchestra BioMed Holdings (OBIO) Receives a Buy from Chardan Capital - The Globe and Mail
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update - Sahm
Orchestra BioMed Holdings, Inc. (OBIO) surpasses Q4 earnings and revenue estimates - MSN
Orchestra BioMed (NASDAQ:OBIO) Receives "Buy" Rating from Chardan Capital - MarketBeat
Chardan reiterates Orchestra BioMed stock rating on trial focus By Investing.com - Investing.com Canada
Chardan reiterates Orchestra BioMed stock rating on trial focus - Investing.com
Orchestra BioMed Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Orchestra BioMed Holdings, Inc. (OBIO) Exceeds Expectations for Q4 Earnings and Revenue - Bitget
Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
OBIO: Revenue up 1,539% to $33.5M; strong cash, pivotal trials advancing, more proceeds expected - TradingView
Orchestra BioMed Reports $106.5 Million Cash Position and Major Financial Milestones for 2025 - Quiver Quantitative
Orchestra BioMed Holdings 10-K Summary — Revenue: $— | EPS: $— - TradingView
Orchestra BioMed Secures $30 Million Terumo Deal for Coronary Device Rights - MSN
Aug Analyst Calls: Will Orchestra BioMed Holdings Inc benefit from AI trendsTrade Risk Summary & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Why Orchestra BioMed Holdings Inc. stock could outperform in 2026Portfolio Update Report & Risk Managed Trade Strategies - Naître et grandir
Insider Sell: How resilient is Orchestra BioMed Holdings Inc. stock in market downturns2025 Key Highlights & Verified Short-Term Trading Plans - Naître et grandir
Orchestra BioMed Holdings Inc. share price - Mint
Market Leaders: Does Orchestra BioMed Holdings Inc outperform in volatile markets2025 Buyback Activity & Stepwise Trade Execution Plans - baoquankhu1.vn
Orchestra BioMed to present hypertension therapy data at medical meetings By Investing.com - Investing.com Canada
Orchestra BioMed announces presentations highlighting Avim therapy potential impact on hypertensive heart disease and heart failure at THT and CRT - marketscreener.com
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT - The Manila Times
Orchestra BioMed to present hypertension therapy data at medical meetings - Investing.com
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
OBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
RTW INVESTMENTS, LP Increases Stake in Orchestra BioMed Holdings Inc - GuruFocus
Medtronic (OBIO) affiliates hold 17.8% of Orchestra BioMed in amended 13G/A - Stock Titan
Earnings Beat: How much upside does Orchestra BioMed Holdings Inc have2025 Fundamental Recap & Accurate Technical Buy Alerts - baoquankhu1.vn
Orchestra BioMed to Present at Two Healthcare Conferences - MyChesCo
Gains Report: Is Tuya Inc Depositary Receipt a play on infrastructure spending - baoquankhu1.vn
OBIOOrchestra BioMed Holdings Inc Latest Stock News & Market Updates - Stock Titan
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Penumbra (PEN), Orchestra BioMed Holdings (OBIO) and Teladoc (TDOC) - The Globe and Mail
Orchestra BioMed grants inducement stock options to nine new employees - MSN
Will Orchestra BioMed Holdings Inc. benefit from geopolitical trendsJuly 2025 Decliners & Real-Time Volume Analysis Alerts - mfd.ru
Orchestra Biomed Holdings Inc Stock (OBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):